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S176 Oral Presentationsv 89.3%; p5 0.2), and history of one or more mammograms
(93.5% v 91.7%; p5 0.51); Males–regular testicular cancer screen-
ing (17.6% v 20.4; p5 0.5) in the past 2 years.
Conclusions: HCT-survivors had similar cancer screening prac-
tices when compared to healthy sibling controls. The current study
found that despite potential long-term risks, survivors continue to en-
gage in high-risk behaviors such as smoking and excessive alcohol in-
take, indicating the need for targeted interventions in the high-risk
populations.58
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Preservation of fertility and the ability to bear children after HCT
can be an important positive influence on the quality of life of young
transplant survivors. We describe 182 pregnancies that were re-
ported to the CIBMTR between 2002 and 2007 among female
HCT recipients (N5 84) or partners of male HCT recipients
(N5 98). Transplant types included autologous (auto) HCT (20
women, 13 men), myeloablative (MA) allogeneic (allo) HCT (50
women, 80 men) and non-myeloablative (NMA) allo HCT (14
women, 5 men). Age at HCT was\10 years for 6% women and
4% men and 10-19 years for 44% women and 16% men. HCT
was performed for a non-malignant disorder in 58% women and
31% men. Conditioning regimen used total body irradiation (TBI)
in 16% women and 20% men. Bu-Cy conditioning was used in
6% women and 40% men. Six women and 6 men had received two
transplants before pregnancy. Fifteen men reported the use of cryo-
preserved sperm to facilitate pregnancy. Among 35 women who re-
ceived HCT for a malignant disorder, 4 had relapsed between HCT
and pregnancy; one was in remission and 3 had persistent disease at
time of pregnancy (Hodgkin’s lymphoma, myeloma and solid can-
cer). Among 66 men with malignant disorders, 12 had relapsed be-
tween HCT and pregnancy; of these 10 achieved a subsequent
remission and were disease free at the time of pregnancy. In sum-
mary, some HCT recipients can retain their fertility, including pa-
tients who have received myeloablative TBI based conditioning
and recipients of more than one HCT. Appropriate patients shouldPregnancy after HCT
Women
Variable Auto MA allo
N 20 54
Median age at HCT, range (yrs) 22 (16-33) 18 (5-45)
Median age at pregnancy, range (yrs) 28 (18-40) 28 (15-50)
Time b/w HCT and pregnancy
#5 years 7 (35%) 15 (28%)
.5 years 13 (65%) 39 (72%)
TBI in conditioning 0 10 (19%)
Median TBI dose (cGy) - 1200
Chronic GVHD - 12 (22%)
Received 2nd HCT* 0 4 ( 8%)
Median followup of survivors 9 yrs 11 yrs
*Two patients received three HCT’s.be counseled about fertility issues both before and after HCT. Out-
comes of pregnancy after HCT need prospective evaluation.59
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Survivors of allogeneic hematopoietic-cell transplantation (allo
HCT) who receive total body irradiation based conditioning
have 2 to 3 folds increased risks of developing second solid cancers
compared to the general population (Rizzo et al, Blood 2009). We
evaluated the risks of second solid cancers (excluding skin squa-
mous and basal cell cancers) in a population of allo HCT recipi-
ents who had received chemotherapy based conditioning. Our
study cohort consisted of 4349 pediatric and adult recipients of
allo HCT using busulfan-cyclophosphamide (Bu-Cy) conditioning
from 1986-2005 for acute myeloid leukemia in first complete re-
mission (AML CR1) or chronic myeloid leukemia in first chronic
phase (CML CP1). Patients with therapy related AML were ex-
cluded. The median followup of survivors was 8.2 years; 47%
had survived .5 years and 18% had survived .10 years after
HCT. Our cohort represented 22,269 person-years at risk. For
the whole cohort, 79% received HCT from HLA identical sib-
lings and 84% had bone marrow as graft source. Median age at
HCT was 29 years for AML and 36 years for CML. Acute (grade
2-4) and chronic graft-versus-host disease (GVHD) occurred in
34% and 33% of AML patients and 42% and 46% of CML pa-
tients, respectively. Sixty-six solid cancers were reported; the cu-
mulative incidence of solid cancers at 3, 5 and 10 years after
HCT was 0.7%, 0.9% and 2.0% for AML patients and 0.5%,
1.1% and 3.4% for CML patients. The overall rate of solid can-
cers among HCT recipients was significantly higher than the ex-
pected general population rates (observed to expected ratio [O/
E] 1.4; 95% confidence intervals 1.1-1.8). Significantly elevated
risks were observed for tumors of the lip (O/E 25.7), tongue
(O/E 9.1), mouth (O/E 7.2), esophagus (O/E 10.3), lung (O/E
2.6), soft tissue (O/E 7.1) and brain (O/E 4.7). On Cox-regression
analysis, older age at HCT, chronic GVHD and use of peripheral
blood as graft source increased the risks of solid cancers while use
of methotrexate (MTX) and cyclosporine (CSA) for GVHD pro-
phylaxis (vs. T-cell depletion) decreased the risks of solid cancers
(Table). Recipients of allo HCT for AML CR1 and CML CP1 us-
ing Bu-Cy conditioning are at risk of developing solid cancers,Men
NMA allo Auto MA allo NMA allo
10 13 81 3
24 (12-33) 28 (20-40) 24 (1-53) 34 (25-49)
26 (18-37) 32 (23-48) 31 (11-55) 35 (32-51)
8 (80%) 4 (31%) 25 (31%) 3 (100%)
2 (20%) 9 (69%) 56 (69%) 0
2 (20%) 1 ( 8%) 18 (22%) 1 (33%)
200 1320 1200 200
3 (30%) - 39 (48%) 2 (67%)
2 (14%) 2 (15%) 3 ( 4%) 1 (33%)
4 yrs 8 yrs 11 yrs 3 yrs
Table 1. Sample Characteristics and Symptom Burden Means
cGVHD
(N5 116)
No cGVHD
(N5 58)
Mean (SD) Mean (SD) P
Age in yrs 49.7 (12.33) 50.6 (15.32) 0.700
Oral Presentations S177especially those with older age, chronic GVHD and recipients of
peripheral blood grafts. The incidence for solid cancers continues
to increase with time and life-long cancer surveillance is warranted
in this population.
Risk factors for solid cancers
Risk factor RR (95%CI) Education in yrs 14.7 (1.85) 14.4 (1.97) 0.340
All symptom items 2.65 (1.69) 1.67 (1.46) \0.0001*Age (years)
Core symptom items 2.34 (1.73) 1.77 (1.62) 0.040*\20 1.0
cGVHD symptom items 3.46 (2.08) 1.39 (1.44) \0.0001*20-40 2.4 (0.7-8.1)
Muscle weakness 3.92 (2.74) 1.57 (1.98) \0.0001*.40 6.2 (1.9-20.4)**
Changes in sexual function 3.70 (3.69) 1.57 (2.70) \0.0001*Chronic GVHD
Skin problems 3.37 (2.99) 0.83 (1.58) \0.0001*No 1.0
Eye problems 3.31 (3.09) 1.22 (2.52) \0.0001*Yes 2.6 (1.5-4.6)**
Joint stiffness of soreness 3.06 (3.20) 1.74 (@.32) 0.006*Graft type
Interference items 3.05 (2.37) 2.38 (2.38) 0.080Bone marrow 1.0Peripheral blood 2.5 (1.3-4.5)**
Number (%) Number (%)GVHD prophylaxisGender 0.023*T-cell depletion (ex-vivo) 1.0
Male 73 (62.9) 26 (44.8)ATG/campath 0.5 (0.1-2.4)
Female 43 (37.1) 32 (55.2)MTX1CSA 0.3 (0.1-0.9)*
Race/Ethnicity 0.472
Black/Hispanic 21 (18.1) 8 (13.8)
White 95 (81.9) 50 (86.2)*P\0.05, **P\0.01.Employment Status 0.433
Employed 48 (41.4) 27 (46.6)
Unemployed 68 (58.6) 31 (53.4)
Marital Status 0.356
Married 82 (70.7) 37 (63.8)
Single 34 (29.3) 21 (36.2)
Performance Status 0.297
Good (0-1) 77 (66.4) 43 (74.1)
Poor (2-4) 39 (33.6) 15 (25.9)
Underlying Disease 0.652
Leukemia 72 (62.1) 38 (65.5)
Lymphoma 33 (28.4) 13 (22.4)
Other 11 (9.5) 7 (12.1)
Donor 0.024*
Related 71 (61.2) 25 (43.1)
Unrelated 45 (38.8) 33 (59.9)
Type of Cells 0.249
Peripheral Stem Cells 83 (71.6) 45 (77.6)
Bone Marrow 29 (25.0) 9 (15.5)
Cord Blood 4 (3.4) 4 (6.8)
Occurrence of Acute GVHD \0.0001*
Yes 77 (66.4) 13 (22.4)
No 39 (33.6) 45 (77.6)
*significant at \0.05 level N5number of subjects P5probability
SD5standard deviation.60
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Significance: Chronic graft-versus-host disease (cGVHD) can
cause debilitating symptoms after allogeneic hematopoietic stem
cell transplantation (alloHSCT). A major barrier to effective
treatment of the symptom burden of cGVHD is inadequate as-
sessment.
Problem and Purpose:The symptom burden of cGVHD cannot be
effectively assessed for research and clinical management without
a psychometrically sound, easily administered measure. The purpose
of this research was to develop a valid, reliable, and sensitive measure
of cGVHD symptom burden, based on the M. D. Anderson Symp-
tom Inventory (core MDASI).
Methods: 116 patients with cGVHD and 58 patients without
cGVHD.3 months after alloHSCT completed the 13 symptom se-
verity and 6 interference items of the core MDASI and 14 additional
cGVHD-specific symptom items, generated from patient interviews
and expert panel ratings. Severity and interference were measured on
a 0-10 scale, with 0 meaning none and 10 meaning the worst imagin-
able. Patients with cGHVD answered a single quality-of-life ques-
tion and 3 days later repeated the symptom burden assessment.
Demographic and disease information was collected on all patients.
Psychometric techniques reduced the number of symptom items and
examined the reliability, validity, and sensitivity of the MDASI for
cGVHD (MDASI-GVH).
Results: Sample demographics, disease characteristics, and symp-
tom severity and interference are shown in Table 1. Five new
cGVHD-related items (see Table 1) were found to be clinically sig-
nificant and were retained in the MDASI-GVH. The reliability in-
dex (Cronbach alpha) and test-retest reliability of all 18 symptom
items were 0.90 and 0.82 respectively and of the 6 interference items
were 0.91 and 0.75 respectively. Factor analysis showed the
cGVHD-related symptom items to be a unique factor. The
MDASI-GVH was sensitive to the presence of cGHVD, was able
to discriminate between patients with good and poor performance
status, and was significantly correlated with patient report of overall
quality of life. Symptom severity explained 77.2% of the variance in
interference, with the core symptoms explaining 76.1% and the
cGVHD-related symptoms explaining 55.9%.Implications: We have validated a new analytic tool, the MDASI-
GVH, for quantifying symptom burden produced by cGVHD.
The MDASI-GVH has the potential to be utilized for quantitatively
assessing response in cGVHD treatment trials and monitoring the
course of cGVHD in clinical care.LEUKEMIA
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EXTRAMEDULLARY RELAPSE IN ACUTE LEUKEMIA FOLLOWING ALLO-
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Extramedullary (EM) relapse after allogeneic hematopoietic cell
transplantation (HCT) for acute leukemia has not been extensively
studied. Therefore, we analyzed 365 consecutive patients (pts) who
